All lobbying filings

THE MADISON GROUP

Lobbying for NOVO NORDISK INC. · Pharmaceutical Company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$90,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.